Results 261 to 270 of about 326,443 (336)

BMI and Breast Subcutaneous Fat

Journal of Ultrasound in Medicine, EarlyView.
Objectives Obesity is closely associated with the occurrence and progression of breast cancer. While body mass index (BMI) is widely used to diagnose obesity, it has certain limitations. Subcutaneous fat thickness (SFT) also serves as an indicator of body composition. However, studies on breast SFT are scarce.
Shiyu Wang, Jin Zhou, Yunxia Huang, Dongdong Zheng, Ruoqing Hou, Shichong Zhou   +5 more
wiley   +1 more source

Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. [PDF]

Mol Cancer Ther
Burke CM, Feinberg TY, Brosius S, Bhanot UK, Jain M, Linkov I, Siddiquee A, Guillan K, Ibáñez G, Ndengu AA, Calder P, Rosales N, Coutinho DF, Long MM, Fishkin R, Thyparambil S, Glade Bender JL, Reed DR, You D, Ortiz MV, Slotkin EK, Kung AL, Dela Cruz FS.   +22 more
europepmc   +1 more source

Supplementary Table S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors

Javier Cortés, Araceli Priego, Elena Garralda, Katerin Rojas, Simon Lord, Thorsten Oliver Goetze, Sherko Kuemmel, Simon J. Crabb, Zinnia P. Parra‐Guillén, Marie Borggren, Ingrid Karlsson, Danijela Lindahl, Linda Mårtensson, Robert Oldham, Anna Ropenga, Ingrid Teige, Johan Wallin, Björn Frendéus, Andrés McAllister   +18 more
openalex   +1 more source

Exome Sequencing Identifies Variants in MLH1 and ERBB2 as Potential Cancer‐Predisposing Factors in Familial Early‐Onset Colorectal Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Colorectal cancer (CRC) has raised considerable health concerns worldwide, with increasing incidence rates, specifically among younger populations. Despite remarkable progress in diagnosing and treating various diseases, the genetic basis of CRC remains only partially understood.
Behnaz Bagheri, Neda Mohsen‐Pour, Najmeh Salehi, Pardis Ketabi Moghadam, Adel Zeinalpour, Amir Sadeghi, Samira Kalayinia, Nayeralsadat Fatemi   +7 more
wiley   +1 more source

Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision. [PDF]

NPJ Breast Cancer
Li M, Cai MY, Lv H, Zhou SL, Zhu YF, Shui RH, Yang WT.   +6 more
europepmc   +1 more source

Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2– advanced breast cancer in postmenopausal women: analysis from a Medicare perspective

Sarah Sammons, Paolo Tarantino, Vijayakrishna K. Gadi, Purnima Pathak, Gary Sopher, Thomas E. Delea, Daniel Stellato   +6 more
openalex   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers. [PDF]

Cancers (Basel)
Bagegni NA, Giridhar KV, Stewart D.
europepmc   +1 more source

Data Sheet 1_Engineering HER2-targeted biparatopic antibodies to promote receptor internalization and restore antitumor efficacy.pdf

Xinlin Liu (1704829), Wanpeng Yu (601803), Yihuan Wang (9601979), Dongming Xing (345609), Haiming Huang (803483), Wenjing Zhu (487218), Peng Sun (112156)   +6 more
openalex   +1 more source

557 The Genomic Landscape of ER Positive, HER2 Negative Breast Cancer

, 2012
Manasa Ramakrishna, Susan Martin, Purdey J. Campbell, P. Andrew Futreal, Michael R. Stratton   +4 more
openalex   +1 more source